Cyclacel Pharmaceuticals Company Profile (NASDAQ:CYCC)

About Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Cyclacel Pharmaceuticals logoCyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CYCC
  • CUSIP: N/A
  • Web: www.cyclacel.com
Average Prices:
  • 50 Day Moving Avg: $1.85
  • 200 Day Moving Avg: $3.37
  • 52 Week Range: $1.56 - $10.90
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.20
  • P/E Growth: 0.00
Profitability:
  • Return on Equity: -68.88%
  • Return on Assets: -50.80%
Debt:
  • Current Ratio: 3.72%
  • Quick Ratio: 3.72%
Misc:
  • Average Volume: 690,822 shs.
  • Beta: 3.35
 

Frequently Asked Questions for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?

Cyclacel Pharmaceuticals's stock reverse split before market open on Tuesday, May 31st 2016. The 1-12 reverse split was announced on Friday, May 27th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 27th 2016. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.50) earnings per share (EPS) for the quarter. View Cyclacel Pharmaceuticals' Earnings History.

Who are some of Cyclacel Pharmaceuticals' key competitors?

Who are Cyclacel Pharmaceuticals' key executives?

Cyclacel Pharmaceuticals' management team includes the folowing people:

  • David Charles U'Prichard Ph.D., Independent Chairman of the Board
  • Spiro George Rombotis, President, Chief Executive Officer, Director
  • Christopher S. Henney Ph.D., Independent Vice Chairman of the Board
  • Paul McBarron, Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director
  • Judy H. Chiao M.D., Vice President - Clinical Development and Regulatory Affairs
  • John Michael Middlecott Banham, Independent Director
  • Samuel L. Barker Ph.D., Independent Director
  • Gregory T. Hradsky, Independent Director
  • Lloyd M. Sems, Independent Director

Who owns Cyclacel Pharmaceuticals stock?

Cyclacel Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include EASTERN CAPITAL LTD (17.70%). Company insiders that own Cyclacel Pharmaceuticals stock include Eastern Capital Ltd and Kevin C Tang. View Institutional Ownership Trends for Cyclacel Pharmaceuticals.

How do I buy Cyclacel Pharmaceuticals stock?

Shares of Cyclacel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cyclacel Pharmaceuticals' stock price today?

One share of Cyclacel Pharmaceuticals stock can currently be purchased for approximately $1.89.


MarketBeat Community Rating for Cyclacel Pharmaceuticals (NASDAQ CYCC)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  52 (Vote Outperform)
Underperform Votes:  40 (Vote Underperform)
Total Votes:  92
MarketBeat's community ratings are surveys of what our community members think about Cyclacel Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cyclacel Pharmaceuticals (NASDAQ:CYCC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Price Target History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Analysts' Ratings History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/12/2016HC WainwrightReiterated RatingBuyN/AView Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Earnings by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Earnings History by Quarter for Cyclacel Pharmaceuticals (NASDAQ CYCC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.50)ViewListenView Earnings Details
5/11/2017Q1 2017($0.38)ViewN/AView Earnings Details
3/28/2017Q4 2016($0.73)($0.69)$0.21 million$0.28 millionViewN/AView Earnings Details
11/14/2016Q316($0.94)($0.86)$0.42 million$0.21 millionViewN/AView Earnings Details
8/10/2016Q216($1.01)$0.22 millionViewListenView Earnings Details
5/11/2016Q116($0.09)$512.00 million$139.00 millionViewListenView Earnings Details
3/24/2016Q4($0.08)($0.10)$0.51 million$0.42 millionViewListenView Earnings Details
11/12/2015Q315($0.09)($0.08)$0.30 million$0.72 millionViewListenView Earnings Details
8/11/2015Q215($0.10)$0.30 millionViewListenView Earnings Details
5/12/2015Q115($0.25)($0.19)$0.51 millionViewListenView Earnings Details
3/24/2015Q414($0.26)($0.21)$0.25 millionViewN/AView Earnings Details
11/11/2014Q314($0.26)($0.22)$0.74 millionViewN/AView Earnings Details
8/12/2014Q214($0.28)($0.22)$0.36 millionViewN/AView Earnings Details
5/13/2014Q114($0.24)($0.25)$0.40 millionViewN/AView Earnings Details
3/25/2014Q413($0.33)($0.19)$0.09 million$0.30 millionViewN/AView Earnings Details
11/12/2013Q3($0.31)($0.31)ViewListenView Earnings Details
8/14/2013Q2 2013($0.10)$0.03 million$0.26 millionViewN/AView Earnings Details
5/13/2013Q1 2013($1.18)ViewN/AView Earnings Details
11/12/2012Q312($0.37)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Current Year EPS Consensus Estimate: $-2.25 EPS
Next Year EPS Consensus Estimate: $-1.57 EPS

Dividends

Dividend History by Quarter for Cyclacel Pharmaceuticals (NASDAQ CYCC)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/9/2016Annual$0.157/13/20167/17/20168/1/2016
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 6.48%
Insider Trades by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Institutional Ownership by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Insider Trades by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/19/2017Eastern Capital LtdMajor ShareholderBuy850,000$2.00$1,700,000.00View SEC Filing  
2/23/2017Kevin C TangMajor ShareholderBuy134,200$4.34$582,428.00View SEC Filing  
11/20/2014Sam L BarkerDirectorBuy3,100$3.00$9,300.00View SEC Filing  
5/21/2013Lloyd SemsDirectorBuy33,333$3.00$99,999.00View SEC Filing  
5/21/2013Paul McbarronCFOBuy12,948$3.03$39,232.44View SEC Filing  
5/21/2013Spiro George RombotisInsiderBuy100,000$3.00$300,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Latest Headlines for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Source:
DateHeadline
seekingalpha.com logoCyclacel Pharmaceuticals (CYCC) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 6:49 PM
globenewswire.com logoCyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 21 at 5:45 PM
thestreet.com logoCyclacel Pharmaceuticals' Preferred Stock Shares Cross 10% Yield Mark
www.thestreet.com - September 19 at 5:44 PM
americanbankingnews.com logoShort Interest in Cyclacel Pharmaceuticals, Inc. (CYCC) Decreases By 35.8%
www.americanbankingnews.com - September 17 at 1:20 AM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Cyclacel Pharmaceuticals and MannKind Corporation
finance.yahoo.com - September 13 at 7:01 PM
seekingalpha.com logoCyclacel Pharmaceuticals (CYCC) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 12 at 6:24 PM
americanbankingnews.com logoShort Interest in Cyclacel Pharmaceuticals, Inc. (CYCC) Drops By 23.5%
www.americanbankingnews.com - August 14 at 2:38 AM
americanbankingnews.com logoCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 10 at 11:04 PM
finance.yahoo.com logoEdited Transcript of CYCC earnings conference call or presentation 9-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 6:58 PM
seekingalpha.com logoCyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 10 at 4:00 AM
globenewswire.com logoCyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 9 at 5:55 PM
streetinsider.com logoCyclacel Pharma (CYCC) Reports Selection of Recommended ... - StreetInsider.com
www.streetinsider.com - August 7 at 11:06 PM
globenewswire.com logoPart 2 of study will focus on cyclin E amplified drug resistant solid tumors
globenewswire.com - August 7 at 6:05 PM
streetinsider.com logoForm 8-K Cyclacel Pharmaceuticals For: Aug 07
www.streetinsider.com - August 7 at 6:05 PM
globenewswire.com logoCyclacel Pharmaceuticals to Release Second Quarter 2017 ... - GlobeNewswire (press release)
globenewswire.com - August 2 at 6:32 PM
globenewswire.com logoCyclacel Announces Closing of $15.2 Million Underwritten Public ... - GlobeNewswire (press release)
globenewswire.com - July 22 at 12:29 AM
nasdaq.com logoCyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option - Nasdaq
www.nasdaq.com - July 21 at 7:27 PM
americanbankingnews.com logoInsider Buying: Cyclacel Pharmaceuticals, Inc. (CYCC) Major Shareholder Purchases 850,000 Shares of Stock
www.americanbankingnews.com - July 21 at 7:10 PM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Cyclacel Pharmaceuticals Inc. and Canadian Solar Inc.
finance.yahoo.com - July 20 at 7:45 PM
globenewswire.com logoCyclacel Announces Pricing of $13.2 Million Underwritten Public Offering
globenewswire.com - July 19 at 6:53 PM
benzinga.com logo22 Stocks Moving In Friday's Pre-Market Session - Benzinga
www.benzinga.com - May 12 at 5:09 PM
seekingalpha.com logoCyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 12 at 3:20 AM
feeds.benzinga.com logoCyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results
feeds.benzinga.com - May 5 at 7:43 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Yingli Green, Calix, Hertz Global, Cyclacel Pharma - Nasdaq
www.nasdaq.com - April 3 at 5:02 PM
rttnews.com logoCyclacel Pharmaceuticals Inc. (CYCC) Is Spiking Higher On CYC065 News - RTT News
www.rttnews.com - April 3 at 5:02 PM
investopedia.com logoCyclacel's CYC065 Succeeds in Lung Cancer Study
www.investopedia.com - April 3 at 5:02 PM
nasdaq.com logoAfter-Hours Earnings Report for March 28, 2017 : PLAY, VRNT, OLLI, SONC, WLB, AST, IZEA, CYCC - Nasdaq
www.nasdaq.com - March 28 at 4:23 PM
biz.yahoo.com logoCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
biz.yahoo.com - March 28 at 4:23 PM
biz.yahoo.com logoQ4 2016 Cyclacel Pharmaceuticals Inc Earnings Release - After Market Close
biz.yahoo.com - March 28 at 12:18 PM
biz.yahoo.com logoCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
biz.yahoo.com - March 13 at 4:43 PM
streetinsider.com logoCyclacel Pharma (CYCC) CDK Inhibitor CYC065 Causes Anaphase Catastrophe Featured in JNCI Publication - StreetInsider.com
www.streetinsider.com - March 9 at 5:11 PM
seekingalpha.com logoCyclacel Pharmaceuticals: Is There Anything Left In The Tank? - Seeking Alpha
seekingalpha.com - March 9 at 5:11 PM
investopedia.com logoCyclacel Plunges on Leukemia Drug Failure (CYCC)
www.investopedia.com - February 24 at 12:00 PM
investopedia.com logoCyclacel Tanks on Leukemia Drug Failure
www.investopedia.com - February 24 at 12:00 PM
streetinsider.com logoCyclacel Pharma (CYCC) Pivotal Phase 3 SEAMLESS Study in Elderly Patients With AML Doesn't Meet Primary Endpoint
www.streetinsider.com - February 23 at 9:39 PM
us.rd.yahoo.com logo6:57 am Cyclacel Pharma announces its Phase 3 SEAMLESS study in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia did not meet its primary endpoint
us.rd.yahoo.com - February 23 at 9:39 PM
us.rd.yahoo.com logoCyclacel's leukemia drug for elderly patients fails in key study
us.rd.yahoo.com - February 23 at 9:39 PM
marketwatch.com logoCyclacel's stock plunges after disappointing trial results of its cancer treatment
us.rd.yahoo.com - February 23 at 9:39 PM
biz.yahoo.com logoCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
us.rd.yahoo.com - February 23 at 9:39 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Tesla, L Brands, Nvidia, Cyclacel - Nasdaq
www.nasdaq.com - February 23 at 4:37 PM
nasdaq.com logoMid-Day Market Update: AXT Rises After Strong Q4 Results; Cyclacel Pharma Shares Tumble - Nasdaq
www.nasdaq.com - February 23 at 4:37 PM
seekingalpha.com logoCyclacel Pharmaceuticals (CYCC) Presents at 19th Annual BIO CEO & Investor Conference
seekingalpha.com - February 14 at 5:26 PM
streetinsider.com logoUnusual 11 Mid-Day Movers 12/27: (MBRX) (CYCC) (RADA) Higher; (ELGX) (SGEN) (GSAT) Lower (more...)
www.streetinsider.com - December 27 at 4:51 PM

Social

Chart

Cyclacel Pharmaceuticals (CYCC) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.